At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 112 enrolled
Drug / intervention
LNP023 +1 moredrug
Likely dose
LNP023 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
In Brief
A Phase 2 clinical trial evaluating LNP023 and Placebo for IgA Nephropathy. Completed, enrolled 112 participants across 56 sites in 25 countries.
Detailed Summary
Efficacy and safety of LNP023 in IgAN patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIgA Nephropathy
CountriesArgentina, Australia, Belgium, Brazil, China, Colombia, Czechia, Denmark, Finland, France, Germany, Hong Kong, India, Israel, Japan, Malaysia, Netherlands, Norway, Singapore, South Korea, Sweden, Taiwan, Thailand, Turkey (Türkiye), United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartFeb 2018
Primary CompletionDec 2020
Study CompletionJun 2021
TodayJul 2026
First PostedDec 14, 2017
Enrollment StartFeb 7, 2018
Primary CompletionDec 29, 2020
Study CompletionJun 22, 2021
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 8.5 years ago
Interventions
LNP023drug
LNP023 5, 25, 100 mg capsles
Placeboother
Matching placebo to LNP023